| Chinula, Lameck |
COVENANT, NCT03284866: HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV |
|
|
| Active, not recruiting | 3 | 536 | RoW | Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine, Recombinant HPV 9-valent Vaccine, Saline, Sodium Chloride 0.9% | AIDS Malignancy Consortium, National Cancer Institute (NCI), University of Arkansas, AIDS and Cancer Specimen Resource, Merck Sharp & Dohme LLC, The Emmes Company, LLC, University of California, Los Angeles | AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection | 12/24 | 03/27 | | |
NCT03601806: Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection |
|
|
| Active, not recruiting | 2 | 26 | RoW | Laboratory Biomarker Analysis, Pomalidomide, 4-Amino thalidomide, Actimid, CC-4047, Imnovid, Pomalyst | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, Montefiore Medical Center, University of Stellenbosch, Weill Medical College of Cornell University, University of California, Los Angeles | Human Immunodeficiency Virus 1 Positive, Skin Kaposi Sarcoma | 11/24 | 01/26 | | |
| Not yet recruiting | 2 | 25 | RoW | Propranolol | AIDS Malignancy Consortium, National Cancer Institute (NCI) | Kaposi Sarcoma | 08/28 | 08/29 | | |
NCT05362955: 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa |
|
|
| Completed | 1 | 12 | RoW | Intravaginal 5-Fluorouracil (5-FU) | UNC Lineberger Comprehensive Cancer Center | CIN 2/3, HIV Infections | 02/24 | 02/24 | | |
NCT04092257: HPV-Based Screen-and-Treat Demonstration Project in Lilongwe |
|
|
| Active, not recruiting | N/A | 1250 | RoW | VIA and thermocoagulation | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI), United States Agency for International Development (USAID) | HPV Infection, Cervical Cancer, HIV Infections | 02/24 | 02/25 | | |
NJIRA, NCT06200545: Improving HIV Prevention Among Heterosexual Cisgender Men Seeking STI Services in Malawi |
|
|
| Enrolling by invitation | N/A | 215 | RoW | PrEP eligibility assessment, Rapid HIV antibody testing prior to provision and/or refill of PrEP, PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines, Evaluation of barriers and facilitators to ongoing PrEP use, Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement, Tracing for any missed PrEP visits, Offering a PrEP "restart" kit for cisgender men who choose to discontinue PrEP during the follow-up period | HIV Prevention Trials Network, Division of AIDS, US National Institute of Allergy and Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection, Sexually Transmitted Infections, Pre-exposure Prophylaxis, Systems Navigation | 06/25 | 06/25 | | |
| Mungo, Chemtai |
NCT06519994: Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya |
|
|
| Recruiting | 2 | 120 | RoW | Artesunate vaginal inserts, Placebo vaginal inserts | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI), Kenya Medical Research Institute, Maseno University School of Medicine, Kenya | Human Immunodeficiency Virus, Human Papillomavirus, Cervical Precancer | 11/25 | 11/25 | | |
NCT06165614: Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya |
|
|
| Recruiting | 1 | 18 | RoW | Artesunate pessary, Colposcopy | UNC Lineberger Comprehensive Cancer Center, Gilead Sciences | Cervix Cancer, Cervix Neoplasm, Precancerous Conditions, Cervical Precancer | 12/25 | 12/25 | | |
NCT06263582: Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya |
|
|
| Completed | 1 | 12 | RoW | Artesunate pessary, blood draws for pharmacokinetics of the study drug | UNC Lineberger Comprehensive Cancer Center | Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3, Cervix; Intraepithelial Neoplasia, Grade I, Cervix; Intraepithelial Neoplasia, Grade II | 08/24 | 08/24 | | |
NCT05362955: 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa |
|
|
| Completed | 1 | 12 | RoW | Intravaginal 5-Fluorouracil (5-FU) | UNC Lineberger Comprehensive Cancer Center | CIN 2/3, HIV Infections | 02/24 | 02/24 | | |
| Painschab, Matthew |
NCT04585893: Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi |
|
|
| Active, not recruiting | 2 | 15 | RoW | Rituximab, Rituxan, Etoposide, Toposar, VP-16 | UNC Lineberger Comprehensive Cancer Center, Fogarty International Center of the National Institute of Health | Multicentric Castleman Disease | 08/25 | 06/27 | | |
| Recruiting | N/A | 180 | RoW | standard of care chemotherapy | UNC Lineberger Comprehensive Cancer Center, National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI) | Kaposi Sarcoma, HIV | 06/27 | 06/27 | | |
| Woodlief, Loretta z |
NCT05362955: 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa |
|
|
| Completed | 1 | 12 | RoW | Intravaginal 5-Fluorouracil (5-FU) | UNC Lineberger Comprehensive Cancer Center | CIN 2/3, HIV Infections | 02/24 | 02/24 | | |
| Gomani, Gabrielle |
| Recruiting | N/A | 180 | RoW | standard of care chemotherapy | UNC Lineberger Comprehensive Cancer Center, National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI) | Kaposi Sarcoma, HIV | 06/27 | 06/27 | | |
